异动解读 | 燃石医学盘中大涨5.13%，学术成果与商业化进展提振投资者信心

异动解读

Oct 28

周二盘中，燃石医学（BNR）股价大涨5.13%，延续了近期的强劲上涨势头。这波涨势背后，是公司在学术研究和商业化方面取得的重要进展，进一步增强了投资者对公司未来发展的信心。

近期，燃石医学在多个国际学术会议上发布了研究成果，主要聚焦DNA/RNA联合检测和低丰度循环肿瘤DNA（ctDNA）检测技术。公司与阿斯利康合作开发的ctDNA检测产品OncoCompass® Plus Prime表现出高度的准确性和可靠性，为双方在癌症诊断领域的深入合作奠定了基础。此外，公司的OncoGuide OncoScreen Plus CDx系统已获得日本厚生劳动省的制造和销售批准，作为阿斯利康AKT抑制剂Truqap的伴随诊断产品，有望在明年上半年进入日本医保体系。

从财务角度来看，燃石医学正稳步向盈利迈进。公司2025年第二季度净亏损大幅收窄至970万元，同比减少91%。分析人士认为，若保持当前净亏损收窄趋势，公司有望在不久的将来实现扭亏为盈。值得注意的是，燃石医学股价自10月21日以来已连续五个交易日上涨，累计涨幅超过60%，显示出投资者对公司前景的看好。然而，相对较低的成交量也反映出主力资金的高度控盘，投资者在参与时需保持谨慎。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179806590"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179806590\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179806590?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-28 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179806590","market":"hk","top_or_hot":-1,"title":"异动解读 | 燃石医学盘中大涨5.13%，学术成果与商业化进展提振投资者信心","media":"异动解读","content":"<p>周二盘中，燃石医学（BNR）股价大涨5.13%，延续了近期的强劲上涨势头。这波涨势背后，是公司在学术研究和商业化方面取得的重要进展，进一步增强了投资者对公司未来发展的信心。</p>\n\n<p>近期，燃石医学在多个国际学术会议上发布了研究成果，主要聚焦DNA/RNA联合检测和低丰度循环肿瘤DNA（ctDNA）检测技术。公司与阿斯利康合作开发的ctDNA检测产品OncoCompass® Plus Prime表现出高度的准确性和可靠性，为双方在癌症诊断领域的深入合作奠定了基础。此外，公司的OncoGuide OncoScreen Plus CDx系统已获得日本厚生劳动省的制造和销售批准，作为阿斯利康AKT抑制剂Truqap的伴随诊断产品，有望在明年上半年进入日本医保体系。</p>\n\n<p>从财务角度来看，燃石医学正稳步向盈利迈进。公司2025年第二季度净亏损大幅收窄至970万元，同比减少91%。分析人士认为，若保持当前净亏损收窄趋势，公司有望在不久的将来实现扭亏为盈。值得注意的是，燃石医学股价自10月21日以来已连续五个交易日上涨，累计涨幅超过60%，显示出投资者对公司前景的看好。然而，相对较低的成交量也反映出主力资金的高度控盘，投资者在参与时需保持谨慎。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 燃石医学盘中大涨5.13%，学术成果与商业化进展提振投资者信心</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 燃石医学盘中大涨5.13%，学术成果与商业化进展提振投资者信心\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-10-28 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>周二盘中，燃石医学（BNR）股价大涨5.13%，延续了近期的强劲上涨势头。这波涨势背后，是公司在学术研究和商业化方面取得的重要进展，进一步增强了投资者对公司未来发展的信心。</p>\n\n<p>近期，燃石医学在多个国际学术会议上发布了研究成果，主要聚焦DNA/RNA联合检测和低丰度循环肿瘤DNA（ctDNA）检测技术。公司与阿斯利康合作开发的ctDNA检测产品OncoCompass® Plus Prime表现出高度的准确性和可靠性，为双方在癌症诊断领域的深入合作奠定了基础。此外，公司的OncoGuide OncoScreen Plus CDx系统已获得日本厚生劳动省的制造和销售批准，作为阿斯利康AKT抑制剂Truqap的伴随诊断产品，有望在明年上半年进入日本医保体系。</p>\n\n<p>从财务角度来看，燃石医学正稳步向盈利迈进。公司2025年第二季度净亏损大幅收窄至970万元，同比减少91%。分析人士认为，若保持当前净亏损收窄趋势，公司有望在不久的将来实现扭亏为盈。值得注意的是，燃石医学股价自10月21日以来已连续五个交易日上涨，累计涨幅超过60%，显示出投资者对公司前景的看好。然而，相对较低的成交量也反映出主力资金的高度控盘，投资者在参与时需保持谨慎。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1179806590","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179806590","pubTimestamp":1761658839,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"周二盘中，燃石医学股价大涨5.13%，延续了近期的强劲上涨势头。这波涨势背后，是公司在学术研究和商业化方面取得的重要进展，进一步增强了投资者对公司未来发展的信心。近期，燃石医学在多个国际学术会议上发布了研究成果，主要聚焦DNA/RNA联合检测和低丰度循环肿瘤DNA检测技术。公司2025年第二季度净亏损大幅收窄至970万元，同比减少91%。分析人士认为，若保持当前净亏损收窄趋势，公司有望在不久的将来实现扭亏为盈。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BNR":"燃石医学"},"translate_title":"Interpretation of changes | Burning Rock Medical rose 5.13% intraday, academic achievements and commercialization progress boosted investor confidence","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"周二盘中，燃石医学（BNR）股价大涨5.13%，延续了近期的强劲上涨势头。这波涨势背后，是公司在学术研究和商业化方面取得的重要进展，进一步增强了投资者对公司未来发展的信心。\n近期，燃石医学在多个国际学术会议上发布了研究成果，主要聚焦DNA/RNA联合检测和低丰度循环肿瘤DNA（ctDNA）检测技术。公司与阿斯利康合作开发的ctDNA检测产品OncoCompass® Plus Prime表现出高度的准确性和可靠性，为双方在癌症诊断领域的深入合作奠定了基础。此外，公司的OncoGuide OncoScreen Plus CDx系统已获得日本厚生劳动省的制造和销售批准，作为阿斯利康AKT抑制剂Truqap的伴随诊断产品，有望在明年上半年进入日本医保体系。\n从财务角度来看，燃石医学正稳步向盈利迈进。公司2025年第二季度净亏损大幅收窄至970万元，同比减少91%。分析人士认为，若保持当前净亏损收窄趋势，公司有望在不久的将来实现扭亏为盈。值得注意的是，燃石医学股价自10月21日以来已连续五个交易日上涨，累计涨幅超过60%，显示出投资者对公司前景的看好。然而，相对较低的成交量也反映出主力资金的高度控盘，投资者在参与时需保持谨慎。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}